Corbus Pharmaceuticals Holdings Inc
XNAS:CRBP 4:00:00 PM EDT
| Market Cap (Intraday) | 141.30M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $8.17 |
| 50-Day MA | $10.68 |
| 200-Day MA | $9.55 |
Corbus Pharmaceuticals Holdings Inc Stock, XNAS:CRBP
500 River Ridge Drive, 2nd floor, Norwood, Massachusetts 02062
United States of America
Phone: +1.617.963.0100
Number of Employees: 28
Description
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFÃ?Å? expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.